.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its top biopharma pick for 2025 and also ranked one more 9 names in the space as obese. The investment financial institution claimed in a keep in mind that it remains to believe “diabesity is readied to come to be.